vs
阿普塔集团（ATR）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
阿普塔集团的季度营收约是Royalty Pharma plc的1.5倍（$962.7M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 7.7%，领先26.7%），阿普塔集团同比增速更快（13.5% vs 4.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 2.6%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ATR vs RPRX — 直观对比
营收规模更大
ATR
是对方的1.5倍
$622.0M
营收增速更快
ATR
高出8.7%
4.8%
净利率更高
RPRX
高出26.7%
7.7%
两年增速更快
RPRX
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $622.0M |
| 净利润 | $74.3M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 11.0% | 62.4% |
| 净利率 | 7.7% | 34.4% |
| 营收同比 | 13.5% | 4.8% |
| 净利润同比 | -26.4% | 2.9% |
| 每股收益（稀释后） | $1.13 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRRPRX
| Q4 25 | $962.7M | $622.0M | ||
| Q3 25 | $961.1M | $609.3M | ||
| Q2 25 | $966.0M | $578.7M | ||
| Q1 25 | $887.3M | $568.2M | ||
| Q4 24 | $848.1M | $593.6M | ||
| Q3 24 | $909.3M | $564.7M | ||
| Q2 24 | $910.1M | $537.3M | ||
| Q1 24 | $915.4M | $568.0M |
净利润ATRRPRX
| Q4 25 | $74.3M | $214.2M | ||
| Q3 25 | $127.9M | $288.2M | ||
| Q2 25 | $111.7M | $30.2M | ||
| Q1 25 | $78.8M | $238.3M | ||
| Q4 24 | $100.9M | $208.2M | ||
| Q3 24 | $100.0M | $544.0M | ||
| Q2 24 | $90.5M | $102.0M | ||
| Q1 24 | $83.1M | $4.8M |
营业利润率ATRRPRX
| Q4 25 | 11.0% | 62.4% | ||
| Q3 25 | 14.2% | 70.1% | ||
| Q2 25 | 14.9% | 36.3% | ||
| Q1 25 | 12.8% | 94.0% | ||
| Q4 24 | 14.2% | 60.9% | ||
| Q3 24 | 15.2% | — | ||
| Q2 24 | 13.8% | 50.2% | ||
| Q1 24 | 12.2% | -13.0% |
净利率ATRRPRX
| Q4 25 | 7.7% | 34.4% | ||
| Q3 25 | 13.3% | 47.3% | ||
| Q2 25 | 11.6% | 5.2% | ||
| Q1 25 | 8.9% | 41.9% | ||
| Q4 24 | 11.9% | 35.1% | ||
| Q3 24 | 11.0% | 96.3% | ||
| Q2 24 | 9.9% | 19.0% | ||
| Q1 24 | 9.1% | 0.8% |
每股收益（稀释后）ATRRPRX
| Q4 25 | $1.13 | $0.49 | ||
| Q3 25 | $1.92 | $0.67 | ||
| Q2 25 | $1.67 | $0.07 | ||
| Q1 25 | $1.17 | $0.55 | ||
| Q4 24 | $1.48 | $0.46 | ||
| Q3 24 | $1.48 | $1.21 | ||
| Q2 24 | $1.34 | $0.23 | ||
| Q1 24 | $1.23 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $618.7M |
| 总债务越低越好 | $1.1B | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $5.3B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ATRRPRX
| Q4 25 | $409.5M | $618.7M | ||
| Q3 25 | $264.8M | $938.9M | ||
| Q2 25 | $169.8M | $631.9M | ||
| Q1 25 | $136.8M | $1.1B | ||
| Q4 24 | $226.2M | $929.0M | ||
| Q3 24 | $327.9M | $950.1M | ||
| Q2 24 | $223.9M | $1.8B | ||
| Q1 24 | $201.1M | $843.0M |
总债务ATRRPRX
| Q4 25 | $1.1B | $9.0B | ||
| Q3 25 | $546.0M | $8.9B | ||
| Q2 25 | $535.1M | $8.0B | ||
| Q1 25 | $561.2M | $7.6B | ||
| Q4 24 | $688.1M | $7.6B | ||
| Q3 24 | $822.7M | $7.6B | ||
| Q2 24 | $681.5M | $7.6B | ||
| Q1 24 | $680.4M | $6.1B |
股东权益ATRRPRX
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.8B | $9.6B | ||
| Q2 25 | $2.7B | $9.5B | ||
| Q1 25 | $2.5B | $9.8B | ||
| Q4 24 | $2.5B | $10.3B | ||
| Q3 24 | $2.5B | $10.3B | ||
| Q2 24 | $2.4B | $9.8B | ||
| Q1 24 | $2.3B | $9.9B |
总资产ATRRPRX
| Q4 25 | $5.3B | $19.6B | ||
| Q3 25 | $5.1B | $19.3B | ||
| Q2 25 | $4.9B | $18.3B | ||
| Q1 25 | $4.5B | $17.6B | ||
| Q4 24 | $4.4B | $18.2B | ||
| Q3 24 | $4.6B | $18.0B | ||
| Q2 24 | $4.5B | $17.7B | ||
| Q1 24 | $4.4B | $16.1B |
负债/权益比ATRRPRX
| Q4 25 | 0.43× | 0.92× | ||
| Q3 25 | 0.20× | 0.93× | ||
| Q2 25 | 0.20× | 0.84× | ||
| Q1 25 | 0.22× | 0.78× | ||
| Q4 24 | 0.28× | 0.74× | ||
| Q3 24 | 0.32× | 0.74× | ||
| Q2 24 | 0.28× | 0.78× | ||
| Q1 24 | 0.29× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | — |
| 自由现金流率自由现金流/营收 | 10.1% | — |
| 资本支出强度资本支出/营收 | 9.0% | — |
| 现金转化率经营现金流/净利润 | 2.47× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $299.6M | — |
8季度趋势，按日历期对齐
经营现金流ATRRPRX
| Q4 25 | $183.7M | $827.1M | ||
| Q3 25 | $177.6M | $702.6M | ||
| Q2 25 | $126.0M | $364.0M | ||
| Q1 25 | $82.7M | $596.1M | ||
| Q4 24 | $178.2M | $742.5M | ||
| Q3 24 | $229.3M | $703.6M | ||
| Q2 24 | $143.6M | $658.2M | ||
| Q1 24 | $92.3M | $664.6M |
自由现金流ATRRPRX
| Q4 25 | $96.9M | — | ||
| Q3 25 | $114.3M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $25.9M | — | ||
| Q4 24 | $112.2M | — | ||
| Q3 24 | $162.7M | — | ||
| Q2 24 | $75.4M | — | ||
| Q1 24 | $16.7M | — |
自由现金流率ATRRPRX
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 1.8% | — |
资本支出强度ATRRPRX
| Q4 25 | 9.0% | — | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 7.5% | — | ||
| Q1 24 | 8.3% | — |
现金转化率ATRRPRX
| Q4 25 | 2.47× | 3.86× | ||
| Q3 25 | 1.39× | 2.44× | ||
| Q2 25 | 1.13× | 12.06× | ||
| Q1 25 | 1.05× | 2.50× | ||
| Q4 24 | 1.77× | 3.57× | ||
| Q3 24 | 2.29× | 1.29× | ||
| Q2 24 | 1.59× | 6.45× | ||
| Q1 24 | 1.11× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
